Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

MicroPhage Receives CE Mark To Market MRSA/MSSA Test In Europe

Designed to rapidly identify MRSA and MSSA infections without costly equipment

MicroPhage has obtained CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage amplification technology. The company’s initial commercial product is designed to rapidly identify Staphylococcus aureus (staph) bacteria as well as determine methicillin resistance (MRSA) or susceptibility (MSSA) in suspected cases of bacteremia bacteria in the blood in five hours.

The MicroPhage MRSA/MSSA blood culture test requires no instrumentation and begins with two small reaction tubes for incubating blood culture specimens. After only five hours, the incubated samples are added to a dual dipstick-like detector, which looks much like a home pregnancy test, claims the company.

One part of the test will identify if the blood sample is infected with S. aureus

bacteria and the other shows whether it is susceptible or resistant to methicillin-type antibiotics. Delivering this diagnostic information quickly will enable physicians to determine more effective and precise antibiotics that could shorten hospital stays.

Steve Lundy, CEO of MicroPhage, said: “Our initial product, as well as the family of tests we intend to offer based on our Bacteriophge Amplification platform, represents a new paradigm for the effective, cost-effective testing of hospital patients. Hospital-acquired infections (HAIs) are a colossal problem, killing more than 15 million1 persons worldwide each year and costing the US $29 billion in unnecessary health care expense. We believe that our initial test will be extremely well received in Europe as well as in the US.

“Our first commercial product establishes a new standard for clinicians in S. aureus identification and antibiotic susceptibility testing, and it is designed to complement the demands of hospitals and laboratories of all sizes. We are developing additional tests, including rapid tests for screening of high-risk patients, skin and soft tissue infections, as well as respiratory infections for S. aureus and other bacteria of clinical interest.”